CervoMed Inc. reports clinical-stage biotechnology developments centered on neflamapimod, an oral small-molecule drug candidate for age-related brain disorders. Company news most often covers dementia with Lewy bodies, the Phase 2b RewinD-LB trial, biomarker and MRI analyses, pharmacokinetic work, formulation and dosing disclosures, and regulatory interactions tied to later-stage development.
Updates also include financial results, grant revenue trends, investor conference presentations, shareholder voting matters, governance items, and capital-structure disclosures. CervoMed has also reported neflamapimod's inclusion in the UK EXPERTS-ALS platform for amyotrophic lateral sclerosis research.
CervoMed (NASDAQ: CRVO) will present Phase 2b RewinD-LB analyses at AD/PD 2026 in Copenhagen, March 17-21, 2026. Presentations include an oral talk on March 21 and a symposium on March 20.
New secondary analyses by pre-specified plasma pTau181 and PK/PD data further support the planned Phase 3 dosing regimen and the chosen patient-enrichment cutoff for DLB patients without Alzheimer’s co-pathology.
CervoMed (NASDAQ: CRVO) announced management will participate in investor conferences in March 2026, including 1x1 investor meetings at the Leerink Global Healthcare Conference on March 11, 2026, and a fireside chat plus meetings at the 38th Annual ROTH Conference on March 23, 2026.
The ROTH fireside chat is scheduled for 12:00–12:30 PM PT on March 23, 2026; the webcast will be accessible in the Investor section of CervoMed's website.
CervoMed (NASDAQ: CRVO) completed a Phase 1 healthy volunteer study evaluating a new, stable crystal form of neflamapimod and selected 50 mg three times daily (TID) as the dosing regimen for its planned Phase 3 trial in dementia with Lewy bodies (DLB).
The company says the stable crystal form's pharmacokinetic profile largely overlaps with the clinically active DP Batch B from the Phase 2b extension; dose is increased to ensure target plasma concentrations are achieved.
CervoMed (NASDAQ: CRVO) announced on Feb 18, 2026 that neflamapimod was selected for inclusion in the UK EXPERTS-ALS platform to evaluate potential ALS treatments.
The randomized, multicenter, open-label trial will measure neurofilament light chain (NfL) in blood; initial evaluation targets ~35 patients for 18–24 weeks, with potential expansion to 80. Trial costs are funded by the UK NIHR and major motor neuron disease charities; first dosing expected by end of 2026.
CervoMed (NASDAQ: CRVO) reported late-breaking Phase 2b RewinD-LB results showing neflamapimod significantly slowed clinical progression in dementia with Lewy bodies (DLB) and reduced the biomarker plasma GFAP. In an extension phase using a new capsule batch (DP Batch B), CDR-SB worsening was 52% lower versus DP Batch A at week 16 (and 82% lower in patients with ptau181 <21 pg/mL). Effects were durable to 32 weeks and correlated with GFAP reductions (median -16.0; p<0.0001). Initial randomized phase did not meet the primary endpoint due to lower-than-expected bioavailability with DP Batch A. CervoMed plans a Phase 3 registrational trial in H2 2026.
CervoMed (NASDAQ: CRVO) presented Phase 2b RewinD-LB biomarker data on December 1, 2025 at CTAD showing neflamapimod reduced plasma GFAP, increased the Aβ42/40 ratio, and trended to lower NfL in dementia with Lewy bodies (DLB).
Key controlled comparison used participants who received a higher-bioavailability capsule batch (DP Batch B) during a 32-week open-label extension versus their prior placebo period; GFAP change correlated with clinical CDR-SB change (r=0.35, p=0.036).
CervoMed (NASDAQ: CRVO) announced that neflamapimod will be featured in two presentations at the 18th CTAD conference, Dec 1–4, 2025 in San Diego.
A late-breaking oral presentation on Dec 4, 2:10 p.m. PT will present full results from the Phase 2b RewinD-LB trial at 32 weeks, delivered by Prof. John-Paul Taylor. A poster (Poster 071) on Dec 1–2 reports that neflamapimod significantly lowers plasma GFAP and examines effects on NfL and Aβ42/40. Plasma assays were run at the Neurochemistry Laboratory, Amsterdam UMC under Prof. Charlotte Teunissen.
CervoMed (NASDAQ: CRVO) reported Q3 2025 results and clinical progress on neflamapimod for dementia with Lewy bodies (DLB). The company said it aligned with the FDA on Phase 3 trial design and plans to meet other global regulators before initiating a global pivotal trial in H2 2026. Phase 2b RewinD-LB 32-week data showed a 64% risk reduction in clinically significant worsening (CDR-SB ≥1.5) in patients with low AD co-pathology (p<0.001) and correlated reductions in plasma GFAP biomarker. Cash on hand was $27.3M (Sept 30, 2025), with funding expected into the third quarter of 2026. Q3 net loss was $7.7M.
CervoMed (NASDAQ: CRVO) announced written FDA feedback aligning on key elements of its planned global Phase 3 trial of neflamapimod for dementia with Lewy bodies (DLB).
The company plans a single, randomized, double-blind, placebo-controlled Phase 3 in ~300 DLB patients, starting in the second half of 2026, with 32-week randomized treatment and a 48-week open-label extension. The primary endpoint is change in CDR-SB; participants with Alzheimer’s co-pathology will be excluded by imaging/CSF and a plasma ptau181 cutoff (≥21.0 pg/mL).
CervoMed (NASDAQ: CRVO) appointed David Quigley to its Board of Directors effective Oct 28, 2025. Mr. Quigley is a former Senior Partner at McKinsey & Company who led Life Sciences and Private Capital practices (Senior Partner 2010–2025) and brings strategy, commercial, transaction, and M&A experience.
The appointment aligns with CervoMed’s near‑term corporate priorities: planned Phase 3 in dementia with Lewy bodies (DLB) and anticipated FDA feedback on Phase 3 design in Q4 2025. Management says Quigley’s network and commercial expertise will support Phase 3 planning, partnering, and potential commercialization of neflamapimod following Phase 2b results.